In vitro synergisms obtained by amphotericin b and voriconazole associated with non-antifungal agents against fusarium spp

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 2, 2011, Pages 126-130

  Venturini, Tarcieli P ^a   Rossato, Luana ^a   Spader, Tatiana B ^a   Tronco Alves, Giordano R ^b   Azevedo, Maria Izabel ^a   Weiler, Caroline B ^a   Santurio, Janio M ^a   Alves, Sydney Hartz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b Hospital Universitario de Santa Maria   (Brazil)

Author keywords

Antifungal agents; Associations; Fusarium spp.; Susceptibility; Synergism

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; CIPROFLOXACIN; FLUINDOSTATIN; IBUPROFEN; ITRACONAZOLE; METRONIDAZOLE; RIFAMPICIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CHECKERBOARD TECHNIQUE; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; FUSARIUM; FUSARIUM CHLAMYDOSPORUM; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG SYNERGISM; FUNGI; FUSARIUM; IBUPROFEN; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 80052858830     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.05.007     Document Type: Article

References (31)

1. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
2. Brunton L.L., Lazo J.S., Parker K.L. Goodmann & Gilman As bases farmacológicas da terapêutica 2007, 1848. MacGraw-Hill Interamericana, Rio de Janeiro. 11th ed.
3. Chin N.X., Weitzman I., Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 1997, 41:850-852.
4. Clancy C.J., Nguyen M.H. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis: in vitro demonstration of synergy. J. Antimicrob. Chemother. 1998, 41:127-130.
5. Clancy C.J., Yu Y.C., Lewin A., Nguyen M.H. Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B. Antimicrob. Agents Chemother. 1998, 42:509-513.
6. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard 2008, CLSI, Wayne, PA. 2nd ed., M38-A2.
7. Córdoba S., Rodero L., Vivot W., Abrantes R., Davel G., Vitale R.G. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int. J. Antimicrob. Agents 2008, 31:171-174.
8. Cuenca-Estrella M. Combinations of antifungal agents in therapy - what value are they?. J. Antimicrob. Chemother. 2004, 54:854-869.
9. Cury A.E., Hirschfeld M.P. Interactions between amphotericin B and nitroimidazoles against Candida albicans. Mycoses 1997, 40:187-192.
10. Edwards J.E., Morrison J., Henderson D.K., Montgomerie J.Z. Combined effect of amphotericin B and rifampin on Candida species. Antimicrob. Agents Chemother. 1980, 17:484-487.
11. Fujita N.K., Edwards J.E. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob. Agents Chemother. 1981, 19:196-198.
12. Guarro J., Pujol I., Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob. Agents Chemother. 1999, 43:1256-1257.
13. Hughes C.E., Harris C., Moody J.A., Peterson L.R., Gerding D.N. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob. Agents Chemother. 1984, 25:560-562.
14. Kitahara M., Seth V.K., Medoff G., Kobayashi G.S. Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob. Agents Chemother. 1976, 9:908-914.
15. Kobayashi G.S., Cheung S.C., Schlessinger D., Medoff G. Effects of rifamycin derivatives, alone and in combination with amphotericin B, against Histoplasma capsulatum. Antimicrob. Agents Chemother. 1974, 5:16-18.
16. Kunin C.M. Antimicrobial activity of rifabutin. Clin. Infect. Dis. 1996, 22:S3-S14.
17. Medoff G. Antifungal activity of rifampin. Rev. Infect. Dis. 1983, 5:614-620.
18. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., Ghannoum M.A. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 2005, 18:163-194.
19. Nash J.D., Burgess D.S., Talbert R.L. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J. Med. Microbiol. 2002, 51:105-109.
20. Natesan S.K., Chandrasekar P.H., Alangaden G.J., Manavathu E.K. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn. Microbiol. Infect. Dis. 2008, 60:369-373.
21. Nucci M., Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. 2002, 35:909-920.
22. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 2007, 20:695-704.
23. Nucci M., Marr K.A., Queiroz-Telles F., Martins C.A., Trabasso P., Costa S., Voltarelli J.C., Colombo A.L., Imhof A., Pasquini R., Maiolino A., Souza C.A., Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2004, 38:1237-1242.
24. O'donnell K., Sarver B.A., Brandt M., Chang D.C., Noble-Wang J., Park B.J., Sutton D.A., Benjamin L., Lindsley M., Padhye A., Geiser D.M., Ward T.J. Phylogenetic diversity and microsphere array-based genotyping of human pathogenic fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006. J. Clin. Microbiol. 2007, 45:2235-2248.
25. Pina-Vaz C., Sansonetty F., Rodrigues A.G., Martinez-de-Oliveira J., Fonseca A.F., Mardh P.A. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J. Med. Microbiol. 2000, 49:831-840.
26. Pujol I., Guarro J., Gené J., Sala J. In vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. 1997, 39:163-167.
27. Raad I.I., Hachem R.Y., Herbrecht R., Graybill J.R., Hare R., Corcoran G., Kontoyiannis D.P. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 2006, 42:1398-1403.
28. Scott E.M., Tariq V.N., McCrory R.M. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob. Agents Chemother. 1995, 39:2610-2614.
29. Spader T.B., Venturini T.P., Cavalheiro A.S., Mahl C.D., Mario D.N., Lara V.M., Santurio J., Alves S.H. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses 2009, 54:131-136.
30. Stergiopoulou T., Meletiadis J., Sein T., Papaioannidou P., Tsiouris I., Roilides E., Walsh T.J. Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob. Agents Chemother. 2008, 52:2196-2204.
31. Stern G.A. In vitro antibiotic synergism against ocular fungal isolates. Am. J. Ophthalmol. 1978, 86:359-367.